FDA approves CartiHeal’s Implant for the Treatment of Cartilage and Osteochondral Defects
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint KFAR SABA, Israel, March 30, 2022 /PRNewswire/ -- CartiHeal Ltd, developer of implants for the treatment of...
Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to date. Most of adverse events are grade 1 or 2. --ASC42 is a novel anti-viral candidate for HBV functional cure through inhibiting the transcription of HBV cccDNA into HBV RNA and reducing the HBV cccDNA stability. HANGZHOU and SHAOXING,...
GenScript Receives “Best Contract Development and Manufacturing Organization Award” For the Third Time in a Row
SINGAPORE, March 30, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the "Best Contract Development and Manufacturing Organization Award" on the Asia Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive year of GenScript bagging the same award in Asia Pacific region. The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract...
BioVaxys Expands Cancer Vaccine Platform
BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platform with BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer ("CRC"). BioVaxys plans to advance...
New home ownership concept in Thailand’s largest property development project combines home with provision of a lifetime of first-class healthcare and wellness services
'The Aspen Tree' branded residences at The Forestias to offer both a home as well as a lifetime of first-class healthcare and wellness services and healthcare insurance included in the purchase price as part of new 'Holistic Lifetime Care' concept Up to US$ 62,000 in introductory discounts and cash credits until 31 May 2022 "The Aspen Tree branded homes...
Terumo and Glooko Announce Collaboration on New Solution for Diabetes Data Sharing
A Technology Integration for MEDISAFE WITHTM Insulin Patch Pump Patients to Upload Data Anytime Anywhere TOKYO, March 30, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, and Glooko, a global leader in data management, remote patient monitoring and mobile apps for people with chronic conditions, have announced...
GILEAD ANNOUNCES NEW DATA REINFORCING CLINICAL BENEFITS OF ITS ANTIVIRAL TREATMENTS AMONG PEOPLE LIVING WITH HEPATITIS B AND C IN ASIA (APASL 2022)
Studies show potential improvement in risk of liver cancer in chronic hepatitis B patients after long-term antiviral treatment Improved renal and bone parameters with tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) across multiple chronic hepatitis B patient types Data on hepatitis C show benefit of sofosbuvir-based regimens ...
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights
SUZHOU, China, March 30, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2021 and highlighted recent progress and upcoming milestones. Highlights First product launch: In November 2021, KN035 (Envafolimab) has received marketing authorization from the Chinese National Medical Products Administration (NMPA), becoming the world's first and currently only subcutaneously...
Qiming’s Portfolio Company Rendu Biotechnology Lists on STAR Market
SHANGHAI, March 30, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company Rendu Biotechnology (SESH: 688193), a leader in RNA molecular diagnostics in China, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 72.65 per share, representing a market cap of CNY 2.9 billion. Qiming Venture Partners...
ZANOPRIMA LIFESCIENCES FILES PATENT INFRINGEMENT ACTION AGAINST HANGSEN INTERNATIONAL TO ENFORCE ITS GROUNDBREAKING ENZYMATIC PROCESS FOR SYNTHESIZING (S)-NICOTINE
WACO, Texas, March 30, 2022 /PRNewswire/ -- On March 12, 2022, Zanoprima Lifesciences Ltd. ("Zanoprima") filed a Complaint for Patent Infringement against Hangsen International Group Ltd. ("Hangsen") in the U.S. District Court, Civil No. 22-cv-00268 ("Complaint"). In its Complaint, Zanoprima alleges that Hangsen has violated its patent entitled "Process for Making (S)-Nicotine," (U.S. Patent No. 10,913,962) ("Zanoprima's Patent")...
